EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic Approaches to Treat SARS‐CoV‐2

Lekhnath Sharma, Neelesh Maheshwari, Nupur Maheshwari, Ghanshyam Teli, Venkatesh Chelvam iD

ChemMedChem · 25.02.2026 · 21 (4)

DOI: 10.1002/cmdc.202500387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 25.02.2026. Verfasst von Lekhnath Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore, Madhya Pradesh, 453552, India. Die Arbeit nennt 154 Literaturangaben. Gefördert von: Indian Institute of Technology Indore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), also known as COVID‐19, spread across the globe, leading to a pandemic. Initially, the drug remdesivir is approved by the FDA for the treatment of SARS‐CoV‐2. Significant efforts have been directed toward epidemiology of the SARS‐CoV‐2 virus to discover potential drug targets that may contribute to the development of effective prevention and treatment strategies. The structure and functions of SARS‐CoV‐2 proteins that may be potential drug targets, including the spike protein, main protease, papain‐like protease, RNA‐dependent RNA polymerase, host proteins like angiotensin‐converting enzyme 2, and transmembrane protease and serine 2, have been thoroughly studied. Biological screening platforms and repurposing have resulted in the discovery of drugs such as nirmatrelvir‐ritonavir (Paxlovid), remdesivir (Veklury), molnupiravir (Lagevrio), anakinra (Kineret), vilobelimab (Gohibic), baricitinib (Olumiant), and tocilizumab (Actemra). The present analysis provides details on the pathogenesis, prevention, diagnosis, clinical characteristics, and potential treatment options currently available worldwide.

Schlagwörter

Stichwörter der Autor:innen

RNA‐dependent RNA polymeraseSARS‐CoV‐2angiotensin‐converting enzymedrug repurposingmain proteasevaccines

Autor:innen und Institutionen

  • Department of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore, Madhya Pradesh, 453552, India.
  • School of Pharmacy, Sangam University, Bhilwara, Rajasthan, 311802, India.
  • School of Pharmacy, Bhupal Noble's University, Udaipur, Rajasthan, 313001, India.
  • Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Khandwa Road, Simrol, Indore, Madhya Pradesh, 453552, India.

ORCID-Profile: Venkatesh Chelvam

Förderung

  • Indian Institute of Technology Indore

Zitieren

APA

Sharma, L., Maheshwari, N., Maheshwari, N., Teli, G., & Chelvam, V. (2026). Therapeutic Approaches to Treat SARS‐CoV‐2. ChemMedChem, 21(4). https://doi.org/10.1002/cmdc.202500387

Vancouver

Sharma L, Maheshwari N, Maheshwari N, Teli G, Chelvam V. Therapeutic Approaches to Treat SARS‐CoV‐2. ChemMedChem. 2026;21(4). doi:10.1002/cmdc.202500387

BibTeX
@article{Sharma2026,
  author = {Sharma, Lekhnath and Maheshwari, Neelesh and Maheshwari, Nupur and Teli, Ghanshyam and Chelvam, Venkatesh},
  title = {Therapeutic Approaches to Treat SARS‐CoV‐2},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {4},
  doi = {10.1002/cmdc.202500387}
}
Kostenlos starten →